This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignees: A2a Pharmaceuticals, Inc., Oncocube Therapeutics LLC. Active years: 2023.
Company Filing History:
1 out of 2 
1 out of 2 Years Active: 2023
Title: Inventor Deniz Lengerli: Pioneering Anticancer Drug Development
Introduction: Deniz Lengerli, an innovative inventor based in Ankara, Turkey, has made significant contributions to the field of cancer research through his patented work. With a focus on developing new therapeutic strategies, Lengerli's contributions in the pharmaceutical industry highlight his commitment to improving cancer treatment options.
Latest Patents: Lengerli holds a notable patent for a highly potent TACC3 inhibitor, designated as a novel anticancer drug candidate. The patent outlines the creation of a new inhibitor chemotype, specifically 3-(4-methoxyphenyl)-N-(2-morpholinopyrimidin-4-yl) isoxazol-5-amine (known as BO-264). This compound targets the TACC3 protein with high potency, functioning as a mitotic blocker to treat breast cancer and potentially other cancer types.
Career Highlights: Throughout his career, Deniz Lengerli has collaborated with leading pharmaceutical companies, including A2A Pharmaceuticals and Oncocube Therapeutics. His experiences at these organizations have provided him with valuable insights into drug development and innovation in oncology.
Collaborations: Lengerli has worked alongside talented professionals, including colleagues Erden Banoglu and Burcu Caliskan. Their collaborative efforts have fostered a dynamic environment conducive to breakthroughs in cancer treatment research.
Conclusion: Deniz Lengerli stands out as a dedicated inventor with a focus on developing advanced treatments for cancer. Through his patented innovations and successful collaborations in the pharmaceutical industry, he continues to pave the way for future advancements in anticancer therapies, demonstrating his commitment to enhancing patient care and outcomes.